LSRF Amidst a Surge in Traditional Chinese Medicine and Volatile Market Conditions

Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. (LSRF) has found itself positioned at the intersection of a robust policy‑driven revival of traditional Chinese medicine (TCM) and an increasingly volatile equity market. While the company’s recent share price—CNY 13.21 as of 28 July 2026—lies comfortably below its 52‑week low of CNY 6.78, it remains anchored by a market capitalization of roughly 4.3 billion CNY and an earnings‑price ratio that has climbed to 87.53, reflecting investors’ cautious optimism about the sector’s long‑term prospects.

Policy Momentum Bolsters the TCM Landscape

In late July, a coalition of 11 ministries and commissions released the Medical and Health Basic Engineering: TCM Action Plan. The policy aims to build a “15‑minute” TCM service network by 2030, enhancing accessibility to preventive, therapeutic, and rehabilitative care at the grassroots level. Key highlights include:

  • Expansion of the National Essential Medicine Catalogue: The 2026 edition now includes 48 newly added TCM formulations, widening the product base available for public procurement.
  • Strengthening of Human Resources and Digital Infrastructure: The plan calls for a surge in trained TCM practitioners and the deployment of digital health tools to support community‑level services.
  • Strategic Integration into the Hierarchical Medical System: TCM is positioned as a complementary modality within the broader disease‑management framework, potentially increasing patient footfall in TCM‑focused facilities.

These developments echo earlier initiatives such as the “15‑5” Plan for TCM Revitalization and the National Health “15‑5” Plan, underscoring a sustained governmental commitment to elevate the TCM sector. Forecasts from Frost & Sullivan project a compound annual growth rate of 9.3 % for the domestic TCM market, expanding from CNY 1.45 trillion in 2024 to CNY 2.26 trillion by 2029.

Market Dynamics: A Day of High Turnover

The Shanghai and Shenzhen exchanges experienced a sharp dip on 30 July 2026, with the SSE Composite falling 0.62 % and the SZSE Component plunging 2.73 %. Amid this broader sell‑off, 45 A‑shares exhibited turnover rates exceeding 20 %, a sign of intensified trading activity. Among these were several TCM‑related names, including Luo Shen Rongfa (ticker 301534) and Luo Sheng Rongfa (ticker 301534). Although LSRF itself was not listed among the high‑turnover stocks, its sectoral peers’ increased activity signals heightened investor scrutiny of TCM‑focused equities.

Competitive Landscape and Peer Performance

The TCM sector has witnessed uneven performance across its constituents. While some companies, such as Luo Sheng Rongfa and Hainan Haiya, enjoyed substantial gains—Hainan Haiya hit its daily limit rise and Luo Sheng Rongfa surged by more than 13 %—others faced headwinds. For instance, Jianke Shiyuan and Xiaolong Pharmaceutical reported declines, illustrating the sector’s fragmented nature.

LSRF’s share price, relative to its peers, sits at a modest valuation. With a price‑earnings ratio of 87.53, the company is trading well above the sector’s average of approximately 23–24, suggesting that investors perceive a premium for its diversified product portfolio that spans traditional medicines, medical devices, and health products. The company’s broad research and development pipeline, coupled with its established distribution network, positions it to capitalize on the policy‑driven demand for quality TCM products.

Investor Sentiment and Outlook

Despite the market’s recent turbulence, sentiment toward TCM has remained largely positive, driven by the confluence of policy support and demographic trends. The aging population and the shift toward preventive health care create a fertile environment for TCM products, which are often perceived as safer alternatives to conventional pharmaceuticals. Furthermore, the inclusion of new TCM formulations in the essential medicine list may lead to higher procurement volumes from public hospitals and community health centers.

LSRF’s management has not announced a new share‑buyback or dividend program in the past two quarters, but the company’s stable cash flow and sizable reserves provide room for future capital‑return initiatives. Analysts expect that, barring macro‑economic shocks, the company could gradually improve its earnings quality and bring its valuation closer to the sector average.

Conclusion

Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. operates within a rapidly evolving TCM ecosystem that is underpinned by aggressive policy interventions and a clear mandate to broaden access to traditional therapies. While short‑term market volatility—highlighted by a day of high turnover on the Shanghai and Shenzhen exchanges—has exerted pressure on share prices across the board, the long‑term trajectory for companies like LSRF remains favorable. Continued investment in research, distribution, and digital health solutions, aligned with governmental priorities, will be critical for sustaining growth and delivering value to shareholders in the years ahead.